X4 Pharmaceuticals (XFOR) Other Non Operating Income (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Other Non Operating Income for 10 consecutive years, with $528000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non Operating Income fell 80.02% year-over-year to $528000.0; the trailing twelve-month figure through Jun 2026 stood at -$68000.0 (down 100.55% YoY), and the FY2025 full-year result was $12.8 million, up 562.76% from the prior year.
• Other Non Operating Income climbed to $528000.0 in Q2 2026 per XFOR's latest filing, from $80000.0 in the prior quarter.
• Across five years, Other Non Operating Income topped out at $25.2 million in Q3 2023 and bottomed at -$13.8 million in Q1 2024.
• Historically, Other Non Operating Income has averaged $2.7 million across 5 years, with a median of $176000.0 in 2022.
• The widest YoY moves for Other Non Operating Income: up 9907.43% in 2024, down 11282.93% in 2024.
• Over 5 years, Other Non Operating Income stood at -$3.8 million in 2022, then jumped by 268.51% to $6.3 million in 2023, then plunged by 88.94% to $700000.0 in 2024, then slumped by 196.57% to -$676000.0 in 2025, then surged by 178.11% to $528000.0 in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $528000.0, $80000.0, and -$676000.0 for Q2 2026, Q1 2026, and Q3 2025 respectively.